New drug shows promise for tough liver cancer cases
NCT ID NCT07536789
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called Becotatug vedotin in 40 adults with advanced liver cancer that has worsened after standard treatments. The goal is to see if it can shrink tumors and help control the disease. Participants receive the drug and are monitored for safety and response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
- Could a common anesthetic help prevent liver cancer from coming back?
- New drug zanzalintinib tested for advanced liver cancer
- New drug cocktail shows promise for tough liver cancer
- Promising drug cocktail targets Hard-to-Treat liver cancer